In a landmark ruling that could reshape the cardiac drug market in India, the Indian Patent Office (IPO) has revoked the patent on Novartis’ blockbuster therapy Vymada, citing lack of novelty and ...
The Novartis case demonstrates that States need not worry about ISDS claims if they act in a non-arbitrary and non-discriminatory manner The Indian Patent Office (IPO) has revoked the patent of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback